Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;174(12):1579-84.
doi: 10.1007/s00431-015-2572-y. Epub 2015 Jun 4.

Sirolimus for the treatment of children with various complicated vascular anomalies

Affiliations

Sirolimus for the treatment of children with various complicated vascular anomalies

Herwig Lackner et al. Eur J Pediatr. 2015 Dec.

Abstract

Vascular anomalies include a heterogeneous group of disorders that are categorized as vascular tumors or vascular malformations. Treatment options include resection, embolization, laser therapy, and sclerotherapy or medical treatment such as propranolol, steroids, interferon, and cytostatic chemotherapy. Mammalian target of rapamycin seems to play a key role in the signal pathway of angiogenesis and subsequently in the development of vascular anomalies. Recently, the successful use of sirolimus has been reported in children with lymphatic malformations and kaposiform hemangioendotheliomas. We report on six patients with different vascular anomalies (kaposiform hemangioendothelioma n = 2, combined lymphatico-venous malformation n = 2, pulmonary lymphangiectasia n = 1, and orbital lymphatic malformation n = 1) who were treated with peroral sirolimus. Three of the children initially presented with a Kasabach-Merrit phenomenon. Median duration of treatment was 10 months; two children are still on treatment. Three children each achieved complete and partial remission. Kasabach-Merrit phenomenon resolved within 1 month in all patients. Treatment with sirolimus was tolerated well; only mild reversible leukopenia was observed.

Conclusion: Sirolimus proved to be effective in children with complicated lymphatic or lymphatico-venous malformations and kaposiform hemangioendotheliomas. Treatment was tolerated well with acceptable side effects. The optimum length of treatment and possible long-term side effects have to be evaluated.

What is known: • Vascular anomalies including vascular tumors and vascular malformations may lead to life-threatening conditions.• Some patients are refractory to established treatment and/or are not available for local invasive procedures.

What is new: • We reviewed the literature focusing treatment of vascular anomalies inc hildren and adolescents.• Our data support recent studies that sirolimus is an effective treatment option in patients with complicated vascular tumors andmalformations

Keywords: Children; Sirolimus; Treatment; Vascular anomalies.

PubMed Disclaimer

References

    1. Laryngoscope. 2011 Sep;121(9):1851-4 - PubMed
    1. Pediatr Blood Cancer. 2011 Dec 1;57(6):1018-24 - PubMed
    1. J Pediatr Hematol Oncol. 2015 Jan;37(1):72-3 - PubMed
    1. Pediatr Clin North Am. 2008 Apr;55(2):339-55, viii - PubMed
    1. Pediatr Blood Cancer. 2007 Jan;48(1):108-11 - PubMed

LinkOut - more resources